Method of treating or reducing cancer comprising administering a compound 3-(benzo[d][1,3]dioxol-5-yl)-7-(1-hydroxypropan-2-yl)-1-(1h-indole-3-yl)-6,7-dihydro-3h-oxazole[3,4-a]pyrazine-5,8-dione

A method of inhibiting a tumor, comprising:

• administering to a subject in need thereof, a compound 3-(benzo [d][1, 3]dioxol-5-yl)-7-(1-hydroxypropan-2-yl)-1-(1H-indole-3-yl)-6, 7-dihydro-3H-oxazole [3, 4-a]pyrazine-5, 8-dione of formula (I)
• or stereoisomers, salts, solvates, hydrates thereof characterized by the fact that the stereoisomers are in their individual separate forms and/or in the forms of racemic mixtures or non-racemic mixtures with diastereoisomer excess in any proportions, or a mixture of stereoisomers characterized by the fact that it is a racemic mixture or a non-racemic mixture.

A method of treating or reducing cancer, comprising:

• administering to a subject in need thereof, an effective amount of a compound 3-(benzo [d][1, 3]dioxol-5-yl)-7-(1-hydroxypropan-2-yl)-1-(1H-indole-3-yl)-6, 7-dihydro-3H-oxazole [3, 4-a]pyrazine-5, 8-dione of formula (I)
• or stereoisomers, salts, solvates, hydrates thereof, characterized by the fact that the stereoisomers are in their individual separate forms and/or in the forms of racemic mixtures or non-racemic mixtures with diastereoisomer excess in any proportions, or a mixture of stereoisomers characterized by the fact that it is a racemic mixture or a non-racemic mixture

A method of treating or reducing the likelihood of benign prostatic hyperplasia and/or prostate cancer, comprising:

• administering to a subject in need thereof, a compound 3-(benzo [d][1, 3]dioxol-5-yl)-7-(1-hydroxypropan-2-yl)-1-(1H-indole-3-yl)-6, 7-dihydro-3H-oxazole [3, 4-a]pyrazine-5, 8-dione of formula (I)
• or stereoisomers, salts, solvates, hydrates thereof, characterized by the fact that the stereoisomers are in their individual separate forms and/or in the forms of racemic mixtures or non-racemic mixtures with diastereoisomer excess in any proportions, or a mixture of stereoisomers characterized by the fact that it is a racemic mixture or a non-racemic mixture.

The method of claim 41, wherein the compound is

• (S)-3-(benzo [d][1,3]dioxol-5-yl)-7-((R)-1-hydroxypropan-2-yl)-1-(1H-indole-3-yl)-6, 7-dihydro-3H-oxazole [3, 4-a]pyrazine-5, 8-dione (BL-239A), represented by formula (VI)
• (R)-3-(benzo [d][1,3]dioxol-5-yl)-7-((R)-1-hydroxypropan-2-yl)-1-(1H-indole-3-yl)-6, 7-dihydro-3H-oxazole [3, 4-a]pyrazine-5, 8-dione (BL-239B), represented by formula (VII)
• the mixture (R)-3-(benzo [d][1, 3]dioxol-5-yl)-7-((R)-1-hydroxypropan-2-yl)-1-(1H-indole-3-yl)-6, 7-dihydro-3H-oxazole [3, 4-a]pyrazine-5, 8-dione with (S)-3-(benzo [d][1,3]dioxol-5-yl)-7-((R)-1-hydroxypropan-2-yl)-1-(1H-indo 1-3-yl)-6, 7-dihydro-3H-oxazole [3, 4-a]pyrazine-5, 8-dione (BL-380), represented by formula (VIII):